TWENTY-FIRST CENTURY GROUP, INC. lobbying for NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX)

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Delaware · House · Senate · $24,000.00 income · posted Jul 20, 2026

Bills named in this filing 3

HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
HR 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
HR 9495
Department of Defense Appropriations Act, 2027

Lobbying activity 4

Health Issues

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Medical/Disease Research/Clinical Labs

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Veterans

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Budget/Appropriations

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD within HR 8646, Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Bill; ALS research and treatment related to HR 9495, Fiscal Year 2027 Defense Appropriations Bill.